The University of Chicago Header Logo

Connection

Richard Koya to Antineoplastic Agents

This is a "connection" page, showing publications Richard Koya has written about Antineoplastic Agents.
Connection Strength

0.455
  1. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41.
    View in: PubMed
    Score: 0.054
  2. Active Immunotherapy of Cancer. Immunol Invest. 2015; 44(8):817-36.
    View in: PubMed
    Score: 0.053
  3. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32.
    View in: PubMed
    Score: 0.050
  4. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79.
    View in: PubMed
    Score: 0.049
  5. Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829.
    View in: PubMed
    Score: 0.049
  6. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81.
    View in: PubMed
    Score: 0.046
  7. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012 Apr 19; 11:22.
    View in: PubMed
    Score: 0.044
  8. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):E1408-16.
    View in: PubMed
    Score: 0.043
  9. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant. 1998 May; 21(9):923-6.
    View in: PubMed
    Score: 0.017
  10. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A. 2017 12 26; 114(52):13679-13684.
    View in: PubMed
    Score: 0.016
  11. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.
    View in: PubMed
    Score: 0.012
  12. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24.
    View in: PubMed
    Score: 0.011
  13. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.